Go Pro
→ 1 Stock to Own by July 31st (From Chaikin Analytics) (Ad)tc pixel Free PIII Stock Alerts

P3 Health Partners (PIII) Competitors

P3 Health Partners logo
$10.43 -0.04 (-0.38%)
Closing price 04:00 PM Eastern
Extended Trading
$10.35 -0.08 (-0.78%)
As of 04:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

PIII vs. LFMD, BDSX, BNR, XGN, and PARK

Should you buy P3 Health Partners stock or one of its competitors? MarketBeat compares P3 Health Partners with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with P3 Health Partners include LifeMD (LFMD), Biodesix (BDSX), Burning Rock Biotech (BNR), Exagen (XGN), and Park Dental Partners (PARK). These companies are all part of the "healthcare" industry.

How does P3 Health Partners compare to LifeMD?

P3 Health Partners (NASDAQ:PIII) and LifeMD (NASDAQ:LFMD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

In the previous week, LifeMD had 1 more articles in the media than P3 Health Partners. MarketBeat recorded 2 mentions for LifeMD and 1 mentions for P3 Health Partners. P3 Health Partners' average media sentiment score of 1.89 beat LifeMD's score of 1.21 indicating that P3 Health Partners is being referred to more favorably in the media.

Company Overall Sentiment
P3 Health Partners Very Positive
LifeMD Positive

7.8% of P3 Health Partners shares are held by institutional investors. Comparatively, 35.5% of LifeMD shares are held by institutional investors. 10.9% of P3 Health Partners shares are held by insiders. Comparatively, 17.2% of LifeMD shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

LifeMD has lower revenue, but higher earnings than P3 Health Partners. P3 Health Partners is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
P3 Health Partners$1.46B0.05-$147.95M-$38.60N/A
LifeMD$194.05M1.12$14.35M$0.0590.20

P3 Health Partners has a beta of 1.62, suggesting that its share price is 62% more volatile than the broader market. Comparatively, LifeMD has a beta of 1.99, suggesting that its share price is 99% more volatile than the broader market.

P3 Health Partners currently has a consensus price target of $14.00, suggesting a potential upside of 34.23%. LifeMD has a consensus price target of $9.14, suggesting a potential upside of 102.72%. Given LifeMD's stronger consensus rating and higher probable upside, analysts plainly believe LifeMD is more favorable than P3 Health Partners.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
P3 Health Partners
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
LifeMD
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.70

LifeMD has a net margin of 2.37% compared to P3 Health Partners' net margin of -8.57%. P3 Health Partners' return on equity of 0.00% beat LifeMD's return on equity.

Company Net Margins Return on Equity Return on Assets
P3 Health Partners-8.57% N/A -19.99%
LifeMD 2.37%-150.88%-22.59%

Summary

LifeMD beats P3 Health Partners on 12 of the 16 factors compared between the two stocks.

How does P3 Health Partners compare to Biodesix?

Biodesix (NASDAQ:BDSX) and P3 Health Partners (NASDAQ:PIII) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.

In the previous week, Biodesix had 1 more articles in the media than P3 Health Partners. MarketBeat recorded 2 mentions for Biodesix and 1 mentions for P3 Health Partners. P3 Health Partners' average media sentiment score of 1.89 beat Biodesix's score of 1.83 indicating that P3 Health Partners is being referred to more favorably in the news media.

Company Overall Sentiment
Biodesix Very Positive
P3 Health Partners Very Positive

Biodesix has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market. Comparatively, P3 Health Partners has a beta of 1.62, indicating that its stock price is 62% more volatile than the broader market.

21.0% of Biodesix shares are owned by institutional investors. Comparatively, 7.8% of P3 Health Partners shares are owned by institutional investors. 23.2% of Biodesix shares are owned by company insiders. Comparatively, 10.9% of P3 Health Partners shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Biodesix has higher earnings, but lower revenue than P3 Health Partners. Biodesix is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biodesix$88.50M2.47-$35.26M-$4.06N/A
P3 Health Partners$1.46B0.05-$147.95M-$38.60N/A

P3 Health Partners has a net margin of -8.57% compared to Biodesix's net margin of -33.26%. P3 Health Partners' return on equity of 0.00% beat Biodesix's return on equity.

Company Net Margins Return on Equity Return on Assets
Biodesix-33.26% -2,101.40% -35.65%
P3 Health Partners -8.57%N/A -19.99%

Biodesix presently has a consensus price target of $28.33, suggesting a potential upside of 34.09%. P3 Health Partners has a consensus price target of $14.00, suggesting a potential upside of 34.23%. Given P3 Health Partners' higher probable upside, analysts clearly believe P3 Health Partners is more favorable than Biodesix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biodesix
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80
P3 Health Partners
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Biodesix beats P3 Health Partners on 9 of the 17 factors compared between the two stocks.

How does P3 Health Partners compare to Burning Rock Biotech?

Burning Rock Biotech (NASDAQ:BNR) and P3 Health Partners (NASDAQ:PIII) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

Burning Rock Biotech has a beta of 1.32, suggesting that its stock price is 32% more volatile than the broader market. Comparatively, P3 Health Partners has a beta of 1.62, suggesting that its stock price is 62% more volatile than the broader market.

P3 Health Partners has a consensus target price of $14.00, suggesting a potential upside of 34.23%. Given P3 Health Partners' stronger consensus rating and higher possible upside, analysts plainly believe P3 Health Partners is more favorable than Burning Rock Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Burning Rock Biotech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
P3 Health Partners
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

P3 Health Partners has a net margin of -8.57% compared to Burning Rock Biotech's net margin of -11.57%. P3 Health Partners' return on equity of 0.00% beat Burning Rock Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
Burning Rock Biotech-11.57% -10.98% -7.33%
P3 Health Partners -8.57%N/A -19.99%

30.0% of Burning Rock Biotech shares are held by institutional investors. Comparatively, 7.8% of P3 Health Partners shares are held by institutional investors. 30.3% of Burning Rock Biotech shares are held by insiders. Comparatively, 10.9% of P3 Health Partners shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Burning Rock Biotech had 1 more articles in the media than P3 Health Partners. MarketBeat recorded 2 mentions for Burning Rock Biotech and 1 mentions for P3 Health Partners. P3 Health Partners' average media sentiment score of 1.89 beat Burning Rock Biotech's score of 0.94 indicating that P3 Health Partners is being referred to more favorably in the news media.

Company Overall Sentiment
Burning Rock Biotech Positive
P3 Health Partners Very Positive

Burning Rock Biotech has higher earnings, but lower revenue than P3 Health Partners. Burning Rock Biotech is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Burning Rock Biotech$77.16M1.36-$7.92M-$0.82N/A
P3 Health Partners$1.46B0.05-$147.95M-$38.60N/A

Summary

P3 Health Partners beats Burning Rock Biotech on 9 of the 16 factors compared between the two stocks.

How does P3 Health Partners compare to Exagen?

Exagen (NASDAQ:XGN) and P3 Health Partners (NASDAQ:PIII) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk and dividends.

P3 Health Partners has a net margin of -8.57% compared to Exagen's net margin of -29.49%. P3 Health Partners' return on equity of 0.00% beat Exagen's return on equity.

Company Net Margins Return on Equity Return on Assets
Exagen-29.49% -94.37% -28.96%
P3 Health Partners -8.57%N/A -19.99%

In the previous week, Exagen had 1 more articles in the media than P3 Health Partners. MarketBeat recorded 2 mentions for Exagen and 1 mentions for P3 Health Partners. P3 Health Partners' average media sentiment score of 1.89 beat Exagen's score of 0.93 indicating that P3 Health Partners is being referred to more favorably in the news media.

Company Overall Sentiment
Exagen Positive
P3 Health Partners Very Positive

Exagen currently has a consensus target price of $9.11, indicating a potential upside of 122.77%. P3 Health Partners has a consensus target price of $14.00, indicating a potential upside of 34.23%. Given Exagen's stronger consensus rating and higher possible upside, analysts plainly believe Exagen is more favorable than P3 Health Partners.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Exagen
1 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.90
P3 Health Partners
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Exagen has higher earnings, but lower revenue than P3 Health Partners. Exagen is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Exagen$66.57M1.48-$19.95M-$0.89N/A
P3 Health Partners$1.46B0.05-$147.95M-$38.60N/A

75.3% of Exagen shares are owned by institutional investors. Comparatively, 7.8% of P3 Health Partners shares are owned by institutional investors. 10.4% of Exagen shares are owned by insiders. Comparatively, 10.9% of P3 Health Partners shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Exagen has a beta of 2.02, meaning that its stock price is 102% more volatile than the broader market. Comparatively, P3 Health Partners has a beta of 1.62, meaning that its stock price is 62% more volatile than the broader market.

Summary

Exagen beats P3 Health Partners on 10 of the 17 factors compared between the two stocks.

How does P3 Health Partners compare to Park Dental Partners?

Park Dental Partners (NASDAQ:PARK) and P3 Health Partners (NASDAQ:PIII) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.

7.8% of P3 Health Partners shares are held by institutional investors. 10.6% of Park Dental Partners shares are held by insiders. Comparatively, 10.9% of P3 Health Partners shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Park Dental Partners and Park Dental Partners both had 1 articles in the media. P3 Health Partners' average media sentiment score of 1.89 beat Park Dental Partners' score of 1.87 indicating that P3 Health Partners is being referred to more favorably in the news media.

Company Overall Sentiment
Park Dental Partners Very Positive
P3 Health Partners Very Positive

Park Dental Partners has a net margin of 0.00% compared to P3 Health Partners' net margin of -8.57%.

Company Net Margins Return on Equity Return on Assets
Park Dental PartnersN/A N/A N/A
P3 Health Partners -8.57%N/A -19.99%

Park Dental Partners has higher earnings, but lower revenue than P3 Health Partners. P3 Health Partners is trading at a lower price-to-earnings ratio than Park Dental Partners, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Park Dental Partners$244.49M0.37-$360K$0.7427.08
P3 Health Partners$1.46B0.05-$147.95M-$38.60N/A

Park Dental Partners currently has a consensus target price of $21.75, suggesting a potential upside of 8.53%. P3 Health Partners has a consensus target price of $14.00, suggesting a potential upside of 34.23%. Given P3 Health Partners' higher probable upside, analysts clearly believe P3 Health Partners is more favorable than Park Dental Partners.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Park Dental Partners
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
2 Strong Buy rating(s)
2.75
P3 Health Partners
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Park Dental Partners beats P3 Health Partners on 8 of the 14 factors compared between the two stocks.

Get P3 Health Partners News Delivered to You Automatically

Sign up to receive the latest news and ratings for PIII and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PIII and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PIII vs. The Competition

Export
MetricP3 Health PartnersMEDICAL INFO SYS IndustryMedical SectorNASDAQ Exchange
Market Cap$75.86M$1.84B$6.85B$12.45B
Dividend YieldN/AN/A2.68%8.43%
P/E Ratio-0.2776.8427.0424.38
Price / Sales0.057.74524.2593.51
Price / CashN/A27.7348.5959.36
Price / Book-0.485.6010.806.33
Net Income-$147.95M-$54.76M$3.59B$331.02M
7 Day Performance-0.95%-2.64%-2.24%-1.09%
1 Month Performance-14.72%4.87%3.12%-0.49%
1 Year Performance65.03%-0.49%26.30%19.90%

P3 Health Partners Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PIII
P3 Health Partners
3.0022 of 5 stars		$10.43
-0.4%		$14.00
+34.2%		+68.1%$75.86M$1.46BN/A500
LFMD
LifeMD
2.8723 of 5 stars		$4.88
-0.6%		$9.14
+87.4%		-57.7%$237.46M$194.05M97.62230
BDSX
Biodesix
3.4867 of 5 stars		$20.34
-6.9%		$28.33
+39.3%		+247.1%$226.27M$88.50MN/A220
BNR
Burning Rock Biotech
1.1294 of 5 stars		$10.74
+4.0%		N/A+153.5%$108.65M$77.16MN/A1,390
XGN
Exagen
3.3908 of 5 stars		$4.80
+9.1%		$9.11
+89.8%		-40.8%$106.30M$66.57MN/A220

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:PIII) was last updated on 7/14/2026 by MarketBeat.com Staff.
From Our Partners
Trump’s $250 Bill – See Immediately
Former Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...
Stansberry Research | Sponsoredtc pixel
When I found Rolls-Royce under $2, most people thought I was crazy
In 2022, Karim Rahemtulla recommended Rolls-Royce when it traded under $2. The stock climbed more than 1,100% ...
Monument Traders Alliance | Sponsoredtc pixel
How much money does your next trade really require?
If a stock trades at $300, most investors assume they need $300 per share. Sean Allison says that assumption m...
Trade Thirsty | Sponsoredtc pixel
Porter flew 3,300 miles to investigate this system
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel
Get the golden rules of day trading for free
Roger Scott spent over three decades trading through the dot-com bust, the financial crisis, the COVID crash, ...
The TradingPub | Sponsoredtc pixel
Urgent: Invest In ‘Elon’s iPhone’ Before July 22nd
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel
ALT SL: These Two Men Who Picked Nvidia Say: “Buy this Elon Supplier”
Jeff Brown and Marc Chaikin - the two investors who picked Nvidia before it climbed as much as 36,000% - are i...
Brownstone Research | Sponsoredtc pixel